Wall Street analysts forecast that Chemed Co. (NYSE:CHE) will report $423.56 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Chemed’s earnings, with the highest sales estimate coming in at $425.40 million and the lowest estimate coming in at $421.72 million. Chemed posted sales of $403.48 million during the same quarter last year, which would indicate a positive year over year growth rate of 5%. The business is scheduled to announce its next quarterly earnings results after the market closes on Wednesday, February 14th.

On average, analysts expect that Chemed will report full year sales of $423.56 million for the current fiscal year. For the next financial year, analysts expect that the business will post sales of $1.73 billion per share, with estimates ranging from $1.69 billion to $1.76 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Chemed.

Chemed (NYSE:CHE) last released its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.73 EPS.

A number of research analysts have recently commented on the company. ValuEngine cut Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research note on Thursday, November 2nd. Royal Bank of Canada raised their target price on Chemed to $232.00 and gave the company a “sector perform” rating in a research note on Tuesday, October 31st. TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Finally, Oppenheimer lifted their price objective on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $236.00.

Chemed (CHE) opened at $263.97 on Thursday. The company has a market capitalization of $4,176.87, a P/E ratio of 58.66, a PEG ratio of 2.94 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. Chemed has a one year low of $163.50 and a one year high of $266.31.

In other Chemed news, CEO Kevin J. Mcnamara sold 10,000 shares of Chemed stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total transaction of $2,234,200.00. Following the completion of the transaction, the chief executive officer now owns 170,016 shares in the company, valued at $37,984,974.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael D. Witzeman sold 1,000 shares of Chemed stock in a transaction on Monday, December 4th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at approximately $833,500. The disclosure for this sale can be found here. Insiders have sold 45,679 shares of company stock valued at $10,628,959 in the last quarter. 4.90% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in CHE. JPMorgan Chase & Co. raised its stake in Chemed by 111.5% during the third quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock valued at $36,125,000 after buying an additional 96,237 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of Chemed by 39.7% in the 2nd quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock worth $43,926,000 after purchasing an additional 61,056 shares in the last quarter. Old Mutual Global Investors UK Ltd. increased its holdings in shares of Chemed by 173.5% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 95,212 shares of the company’s stock worth $19,237,000 after purchasing an additional 60,399 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Chemed by 248.5% in the 2nd quarter. Renaissance Technologies LLC now owns 70,400 shares of the company’s stock worth $14,399,000 after purchasing an additional 50,200 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Chemed by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock worth $374,435,000 after purchasing an additional 34,938 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Chemed Co. (CHE) Expected to Announce Quarterly Sales of $423.56 Million” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/18/chemed-co-che-expected-to-announce-quarterly-sales-of-423-56-million.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Get a free copy of the Zacks research report on Chemed (CHE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.